Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. It is taken orally. Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors. The drug was originated by Pfizer and is under development by Cerevel Therapeutics. As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy. It was also previously under development for Parkinson's disease and cognition disorders, but development for these indications was discontinued.
See also List of investigational cognition and memory disorder drugs List of investigational Parkinson's disease drugs 6-Br-APB Mevidalen (LY-3154207) PF-06412562 Tavapadon (CVL-751)
References
External links CVL-871 - AdisInsight CVL-871 - Cerevel Therapeutics